Inhibition of neointimal formation in porcine coronary artery by a Ras mutant.
BACKGROUND
Therapeutic approaches to reduce the neointimal formation caused by balloon injury have been focused mainly on experimental models of restenosis in the rat carotid artery. However, restenosis in rat carotid artery may not replicate the coronary arterial responses to injury in larger animals and humans.


METHODS
In this study, we used pig coronary arteries as an animal model to evaluate the preventive effects of a virus-mediated dominant negative mutant RasN17 on balloon injury-induced restenosis. The viral particles were delivered to the balloon-injured coronary arteries via a dispatch catheter to keep the virus in a confined arterial segment for 10 min to reach optimal transfection. Six weeks after balloon injury, the pigs were sacrificed and the left anterior descending arteries were isolated for histological analysis.


RESULTS
Neointima formation was prominent in the group receiving balloon injury as compared with the uninjured controls. A remodeling process with migration of collagen was also found in the injured coronary arteries. The application of AdRasN17 led to a 56% decrease in neointima formation and a 75% increase in lumen size, as compared with the balloon-injured vessels treated with AdLacZ control.


CONCLUSIONS
These results suggest that AdRasN17 is an effective therapeutic gene in preventing balloon injury-induced neointimal formation in pig coronary arteries.
Wu
C H
CH
School of Medicine, China Medical College, Taiwan.
Lin
C S
CS
Hung
J S
JS
Wu
C J
CJ
Lo
P H
PH
Jin
G
G
Shyy
Y J
YJ
Mao
S J
SJ
Chien
S
S
D000818:Animals; D001158:Arteries; D002455:Cell Division / Q000187:drug effects; D017023:Coronary Angiography; D003327:Coronary Disease / Q000209:etiology / Q000473:pathology; D003331:Coronary Vessels / Q000293:injuries* / Q000473:pathology / Q000503:physiopathology; D009154:Mutation; D013552:Swine; D017539:Tunica Intima / Q000293:injuries* / Q000473:pathology / Q000503:physiopathology; D014947:Wounds and Injuries / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D018631:ras Proteins / Q000235:genetics* / Q000627:therapeutic use*
D018631:ras Proteins